All Journals > Clinical Infectious Diseases > 15 November 2006 > 24‐Week Efficacy of Tipranavir/Ritonavir

Article Tools

Search for Related Articles

  • By Author
  • Search In

Announcements

CID LISTED AMONG
“MOST INFLUENTIAL”

Clinical Infectious Diseases has been named as one of the "100 Most Influential Journals in Biology and Medicine" of the past 100 years by the Special Libraries Association. The list was compiled by the 680-plus members of SLA’s Biomedical and Life Sciences Division.

See the full list here.

Source: The DBIO 100, the 100 Most Influential Journals in Biology & Medicine over the last 100 Years

In the News

Featured in MSNBC
"Germs and flu are up; infection control is down" June 9, 2009
Trends in the Incidence of Methicillin‐Resistant Staphylococcus aureus Infection in Children’s Hospitals in the United States
Jeffrey S. Gerber, Susan E. Coffin, Sarah A. Smathers, and Theoklis E. Zaoutis
Just this week, researchers reported that the incidence of MRSA infections among children admitted to pediatric hospitals in the United States more than tripled between 2002 and 2007. Researchers at the Children’s Hospital of Philadelphia and the University of Pennsylvania found cases of MRSA jumped from 6.7 per 1,000 admissions in 2002 to 21.1 cases per 1,000 admissions in 2007, according to a study released online Monday in the journal Clinical Infectious Diseases.

Featured in Toronto Star
"Pigs, viruses and politics" May 2, 2009
Are Swine Workers in the United States at Increased Risk of Infection with Zoonotic Influenza Virus?
Kendall P. Myers, Christopher W. Olsen, Sharon F. Setterquist, Ana W. Capuano, Kelley J. Donham, Eileen L. Thacker, James A. Merchant, and Gregory C. Gray
Another study, this one published in the U.S. journal Clinical Infectious Diseases in 2006, found that workers in meat-processing plants have a greater likelihood of being infected by some version of the H1N1 flu virus than the general population (the odds of pig farmers getting the disease are significantly greater again).

Featured in Philadelphia Inquirer
"A shot in the arm for vaccines" April 19, 2009
Vaccines: Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection
Lisa A. Jackson and Edward N. Janoff
Every year, an estimated 915,000 people 65 and older get pneumonia, and 40 percent of them end up in hospitals, according to a 2004 paper in the journal Clinical Infectious Diseases. Pneumonia often kills older people, said Richard Stefanacci, a geriatrician at the University of the Sciences in Philadelphia.

15 November 2006

Volume 43, Number 10
Clinical Infectious Diseases 2006;43:1337–1346
© 2006 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2006/4310-0019$15.00
DOI: 10.1086/508353
HIV/AIDS MAJOR ARTICLE

Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment‐Experienced Patients: 24‐Week Analysis from the RESIST‐1 Trial

Joseph Gathe,1

David A. Cooper,10

Charles Farthing,2

Dushyantha Jayaweera,3

Dorece Norris,5

Gerald Pierone, Jr.,6

Corklin R. Steinhart,4

Benoit Trottier,8

Sharon L. Walmsley,9

Cassy Workman,11

Geoffrey Mukwaya,7

Veronika Kohlbrenner,7

Catherine Dohnanyi,7

Scott McCallister,7 and

Douglas Mayers,7 for the

RESIST‐1 Study Groupa

1Therapeutic Concepts, Houston, Texas; 2AIDS Healthcare Foundation, Los Angeles, California; 3University of Miami School of Medicine and 4Steinhart Medical Associates, Miami, 5Comprehensive Research Institute, Tampa, and 6AIDS Research and Treatment Center of the Treasure Coast, Fort Pierce, Florida; 7Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut; 8Centre de Recherche en Toxicologie de l’Environnement, Universite du Quebec a Montreal, Montreal, and 9University of Toronto, Ontario, Canada; 10National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, and 11AIDS Research Initiative/Ground Zero Medical, Sydney, Australia

Background.Improved treatment options are needed for patients infected with multidrug‐resistant human immunodeficiency virus type 1 (HIV‐1). The nonpeptidic protease inhibitor tipranavir has demonstrated antiviral activity against many protease inhibitor–resistant HIV‐1 isolates. The Randomized Evaluation of Strategic Intervention in multi‐drug reSistant patients with Tipranavir (RESIST‐1) trial is an ongoing, open‐label study comparing the efficacy and safety of ritonavir‐boosted tipranavir (TPV/r) with an investigator‐selected ritonavir‐boosted comparator protease inhibitor (CPI/r) in treatment‐experienced, HIV‐1–infected patients.

Methods.Six hundred twenty antiretroviral‐experienced patients were treated at 125 sites in North America and Australia. Before randomization, all patients underwent genotypic resistance testing, which investigators used to select a CPI/r and an optimized background regimen. Patients were randomized to receive TPV/r or CPI/r and were stratified on the basis of preselected protease inhibitor and enfuvirtide use. Treatment response was defined as a confirmed reduction in the HIV‐1 load of 1 log10 less than the baseline level without treatment change at week 24.

Results.Mean baseline HIV‐1 loads and CD4+ cell counts were 4.74 log10 copies/mL and 164 cells/mm3, respectively. At week 24, a total of 41.5% of patients in the TPV/r arm and 22.3% in the CPI/r arm had a 1‐log10 reduction in the HIV‐1 load (intent‐to‐treat population; ). Mean increases in the CD4+ cell count of 54 and 24 cells/mm3 occurred in the TPV/r and CPI/r groups, respectively. Adverse events were slightly more common in the TPV/r group and included diarrhea, nausea, and vomiting. Elevations in alanine and aspartate aminotransferase levels and in cholesterol/triglyceride levels were more frequent in the TPV/r group.

Conclusions.TPV/r demonstrated superior antiviral activity, compared with investigator‐selected, ritonavir‐boosted protease inhibitors, at week 24 in treatment‐experienced patients with multidrug‐resistant HIV‐1 infection.

Received 23 February 2006; accepted 6 July 2006; electronically published 17 October 2006.

Reprints or correspondence: Dr. Joseph Gathe, Therapeutic Concepts, 4900 Fannin St., PA Houston, TX 77004 ().

Cited by

J. Macias, F. Orihuela, A. Rivero, P. Viciana, M. Marquez, J. Portilla, M. J. Rios, L. Munoz, J. Pasquau, M. A. Castano, L. Abdel-Kader, J. A. Pineda, . (2008) Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis. Journal of Antimicrobial Chemotherapy 63:1, 178-183
Online publication date: 18-Nov-2008.
CrossRef
Juan C Salazar, Pedro Cahn, Ram Yogev, Marinella Della Negra, Guido Castelli-Gattinara, Claudia Fortuny, Patrica M Flynn, Carlo Giaquinto, Ping K Ruan, M Elizabeth Smith, Jaromir Mikl, Ante Jelaska. (2008) Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. AIDS 22:14, 1789-1798
Online publication date: 1-Oct-2008.
CrossRef
J. Borras-Blasco, A. Navarro-Ruiz, C. Borras, E. Castera. (2008) Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. Journal of Antimicrobial Chemotherapy 62:5, 879-888
Online publication date: 18-Aug-2008.
CrossRef
Kristin H Busse, Scott R Penzak. (2008) Pharmacological enhancement of protease inhibitors with ritonavir: an update. Expert Review of Clinical Pharmacology 1:4, 533-545
Online publication date: 1-Aug-2008.
CrossRef
Jennifer J Kiser. (2008) Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV. Current Opinion in HIV and AIDS 3:3, 330-341
Online publication date: 1-Jun-2008.
CrossRef
Mark S. Sulkowski. (2008) Management of Hepatic Complications in HIV‐Infected Persons. The Journal of Infectious Diseases 197:s3, S279-S293
Online publication date: 15-May-2008.
Abstract-Full Text-PDF Version (390 kB)
Joseph J. Eron. (2008) Managing Antiretroviral Therapy: Changing Regimens, Resistance Testing, and the Risks from Structured Treatment Interruptions. The Journal of Infectious Diseases 197:s3, S261-S271
Online publication date: 15-May-2008.
Abstract-Full Text-PDF Version (468 kB)
Sharon L Walmsley, Christine Katlama, Adriano Lazzarin, Keikawus Arestéh, Gerald Pierone, Gary Blick, Margaret Johnson, Ulrich Meier, Thomas R MacGregor, Johnathan G Leith. (2008) Pharmacokinetics, Safety, and Efficacy of Tipranavir Boosted With Ritonavir Alone or in Combination With Other Boosted Protease Inhibitors as Part of Optimized Combination Antiretroviral Therapy in Highly Treatment-Experienced Patients (BI Study 1182.51). JAIDS Journal of Acquired Immune Deficiency Syndromes 47:4, 429-440
Online publication date: 1-May-2008.
CrossRef
M. Battegay, J. Fehr, U. Fluckiger, L. Elzi. (2008) Antiretroviral therapy of late presenters with advanced HIV disease. Journal of Antimicrobial Chemotherapy 62:1, 41-44
Online publication date: 1-May-2008.
CrossRef
Jennifer S Orman, Caroline M Perry. (2008) Tipranavir. Drugs 68:10, 1435-1463
Online publication date: 1-Feb-2008.
CrossRef
Erik De Clercq. (2008) The design of drugs for HIV and HCV. Nature Reviews Drug Discovery 6:12, 1001-1018
Online publication date: 1-Jan-2008.
CrossRef
Sabine Yerly, Viktor von Wyl, Bruno Ledergerber, Jürg Böni, Jörg Schüpbach, Philippe Bürgisser, Thomas Klimkait, Martin Rickenbach, Laurent Kaiser, Huldrych F Günthard, Luc Perrin. (2007) Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 21:16, 2223-2229
Online publication date: 1-Nov-2007.
CrossRef
Sharon L Walmsley, Laurent Cotte, Stefano Rusconi, Douglas J Ward, Charles B Hicks, Ulrich Meier, Hernan Valdez, Charles AB Boucher. (2007) Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. AIDS 21:16, 2245-2248
Online publication date: 1-Nov-2007.
CrossRef
Martin Markowitz, Leonard N Slater, Robert Schwartz, Powel H Kazanjian, Bruce Hathaway, David Wheeler, Mitchell Goldman, Dietmar Neubacher, Douglas Mayers, Hernan Valdez, Scott McCallister. (2007) Long-Term Efficacy and Safety of Tipranavir Boosted With Ritonavir in HIV-1-Infected Patients Failing Multiple Protease Inhibitor Regimens. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:4, 401-410
Online publication date: 1-Sep-2007.
CrossRef
Carmen de Mendoza, Judit Morelló, Pilar Garcia-Gascó, Sonia Rodríguez-Novoa, Vincent Soriano. (2007) Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. Expert Opinion on Pharmacotherapy 8:6, 839-850
Online publication date: 1-May-2007.
CrossRef
Back to Top
Close Popup